Results 141 to 150 of about 225,025 (354)

Patent Landscape of Influenza A Virus Prophylactic Vaccines and Related Technologies [PDF]

, 2012
Executive Summary: This report focuses on patent landscape analysis of technologies related to prophylactic vaccines targeting pandemic strains of influenza.
Barton, Jeremy, Cavicchi, Jon R., Janovetz, Jeffrey, Kowalski, Stanley P., Pflugh, David L., Schroeder, John   +5 more
core   +1 more source

Advances in protein subunit vaccines against H1N1/09 influenza

Frontiers in Immunology
The A/H1N1pdm09 influenza virus, which caused the 2009 pandemic, has since become a recurring strain in seasonal influenza outbreaks. Given the ongoing threat of influenza, protein subunit vaccines have garnered significant attention for their safety and
Yu Zhang, Yu Zhang, Jingyao Gao, Wenqi Xu, Xingyu Huo, Jingyan Wang, Yirui Xu, Wenting Ding, Zeliang Guo, Rongzeng Liu   +9 more
doaj   +1 more source

Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study

Arthritis &Rheumatology, EarlyView.
Objective The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) syndrome. Methods This multicenter international study includes patients with VEXAS from France, Israel, and Italy treated with ...
Tali Eviatar, Dafne Capelusnik, Corrado Campochiaro, Valentin Lacombe, Vincent Jachiet, Michael Zisapel, Iftach Sagy, Oshrat E. Tayer‐Shifman, David Ozeri, Shaye Kivity, Alessandro Tomelleri, Benjamin Terrier, Hagit Peleg, Thibault Comont, Karim Sacre, Pascal Woaye‐Hune, Laurent Arnaud, Estibaliz Lazaro, Vincent Grobost, Francois Lifermann, Maxime Samson, Samuel Ardois, Alice Garnier, Alexandre Maria, Alain Cantagrel, Aurore Meyer, Jean‐David Bouaziz, Mael Heiblig, Lorenzo Dagna, Elisa Diral, Olivier Kosmider, Ori Elkayam, Jérôme Hadjadj, Sophie Georgin‐Lavialle, Olivier Fain, Arsene Mekinian   +35 more
wiley   +1 more source

The need for novel influenza vaccines in low- and middle-income countries: A narrative review

Brazilian Journal of Infectious Diseases
Influenza viruses cause 3–5 million severe cases and 300,000–600,000 deaths worldwide. Most of the disease burden is in Low- and Middle-Income Countries (LMICs) owing to factors such as high population density, infrastructure challenges, poor quality ...
Julia R. Spinardi, Karan B. Thakkar, Verna L. Welch, Oladayo Jagun, Moe H. Kyaw   +4 more
doaj   +1 more source

Identification of histone deacetylase inhibitor targeting type I interferon and B‐cell abnormalities in systemic lupus erythematosus

Arthritis &Rheumatology, Accepted Article.
Objective Systemic lupus erythematosus (SLE) is characterized by increased type I interferon (IFN‐I) and autoantibody production. This study aimed to identify drugs that can inhibit both IFN‐I and autoantibody production. Methods We identified an inhibitor of IFN‐I production from a chemical library.
Takehiro Hirayama, Hachiro Konaka, Yasuhiro Kato, Takayuki Shibahara, Chisato Nishizawa, Kohei Tsujimoto, JeongHoon Park, Eri Itotagawa, Tatsunori Jo, Masayuki Nishide, Sumiyuki Nishida, Yoshihito Shima, Masashi Narazaki, Wataru Aoki, Ken J Ishii, Hyota Takamatsu, Atsushi Kumanogoh   +16 more
wiley   +1 more source

Vaccination nation? Civilised strategies for protecting outdoor poultry from Avian Flu H5N1 [PDF]

, 2006
An analysis of the threat of H5N1 Avian Flu virus to the UK, the potential impact on UK organic and free range poultry production and the evidence for a policy of ...
Sanders, Richard
core  

A Phase I, Randomized, Controlled Trial to Study the Reactogenicity and Immunogenicity of a Nasal, Inactivated Trivalent Influenza Virus Vaccine in Healthy Adults [PDF]

, 2005
Scott A. Halperin, Bruce R. Smith, Kevin Clarke, John Treanor, Taoufik Mabrouk, Marc Germain   +5 more
openalex   +1 more source

Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14–16 June 2010 [PDF]

, 2013
William Ampofo, Norman W. Baylor, Sarah Cobey, Nancy J. Cox, Sharon Daves, S. Edwards, Neil M. Ferguson, Gary Grohmann, Alan Hay, Jacqueline M. Katz, Kornnika Kullabutr, Linda C. Lambert, Roland Levandowski, A. C. Mishra, Arnold S. Monto, Marilda Mendonça Siqueira, Masato Tashiro, Anthony L. Waddell, Niteen Wairagkar, John Wood, Maria Zambon, Wenqing Zhang, Wenqing Zhang   +22 more
openalex   +1 more source

Engineered Stable, Antibiotic‐Free, High‐Level Protein Expression in the Probiotic Chassis Escherichia coli Nissle 1917

Biotechnology and Bioengineering, EarlyView.
The probiotic E. coli Nissle 1917 was engineered to enable stable and antibiotic free protein expression platforms using native plasmids. Further modification aids in the production of high‐level protein expression for antimicrobial secretion whose activity is comparable to industry standard E. coli BL21.
Halimatun Sakdiah Zainuddin, Sanjeeva Kumar Murali, Thomas J. Mansell   +2 more
wiley   +1 more source

Cost Effectiveness of Quadrivalent Influenza Vaccine Over Trivalent Vaccine in France [PDF]

, 2014
G. Duru, Fabrice Carrat, C. Pribil, François Bricaire, P. Pujol, J. Robert, A Lafuma   +6 more
openalex   +1 more source